Pharming (PHAR) Short term Debt (2019 - 2022)

Pharming (PHAR) has 8 years of Short term Debt data on file, last reported at $92.4 million in Q2 2026.

• Quarterly Short term Debt rose 1.24% year-over-year to $92.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $92.4 million (up 1.24% YoY) and the FY2025 annual result came in at $92.7 million, up 168.72% from the prior year.
• Short term Debt declined to $92.4 million in Q2 2026, from $93.4 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $135.6 million in Q1 2022 to a low of -$134.9 million in Q3 2024.
• A 5-year average of $72.4 million and a median of $92.6 million in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2023 — Short term Debt jumped 108006.33% — and 2024, when it tumbled 204.01%.
• Tracing PHAR's Short term Debt over 5 years: stood at $1.8 million in 2022, then rose by 3.17% to $1.8 million in 2023, then soared by 132.73% to $4.2 million in 2024, then jumped by 2084.19% to $92.7 million in 2025, then fell by 0.34% to $92.4 million in 2026.
• The last three Short term Debt figures came in at $92.4 million (Q2 2026), $93.4 million (Q1 2026), and $92.7 million (Q4 2025), per Business Quant data.